期刊文献+

达沙替尼衍生物的合成及其产率分析

Synthesis and yield analysis of dasatinib derivatives
下载PDF
导出
摘要 [目的]制备达沙替尼丁二酸单酯衍生物(DAS⁃SA)并建立分析产率的方法。[方法]采用核磁共振氢谱法确认达沙替尼丁二酸单酯衍生物的合成并采用高效液相色谱法(HPLC),以DAS为对照品间接测定产物中DAS⁃SA的百分含量(即纯度),最后对该反应的产率进行计算。[结果]达沙替尼丁二酸单酯衍生物被成功合成,且反应条件较为温和,通过高效液相色谱法定量分析得到反应产率为71.16%。[结论]建立的高效液相色谱法对DAS衍生物进行定量分析具有快速高效、专属性好、准确度高等优点,可为达沙替尼衍生物的含量测定提供方法依据。 [Objective]To prepare dasatinib succinic acid monoester derivative DAS⁃SA and establish a method for analyzing the yield.[Methods]the synthesis of dasatinib succinic acid monoester derivative was confirmed by 1H NMR and the percentage content purity of DAS⁃SA in the product was indirectly determined by high performance liquid chromatography HPLC with DAS as the control substance.Finally the yield of the reaction was calculated.[Results]Dasatinib succinate monoester derivatives were synthesized successfully and the reaction conditions were mild.The reaction yield was 71.16%by high performance liquid chromatography HPLC.[Conclusion]The highperformance liquid chromatography established in this experiment has the advantages of high speed high efficiency good specificity and high accuracy for the quantitative analysis of DAS derivatives which can provide a method basis for the determination of dashatinib derivatives.
作者 王延玲 袁琦 蒲晓辉 WANG Yanling;YUAN Qi;PU Xiaohui(Institute of Drug Research Henan University,Kaifeng 475001 China)
出处 《河南大学学报(医学版)》 2021年第4期235-239,共5页 Journal of Henan University:Medical Science
基金 河南省教育厅科学技术研究重点项目(19A350001) 开封市科技发展计划项目(1903034,1908006)。
关键词 达沙替尼 酯化反应 高效液相色谱 产率分析 dasatinib esterification high performance liquid chromatography yield analysis
  • 相关文献

参考文献6

二级参考文献48

  • 1冯宝民,韩鑫龙,李雨桐,袁立霞,孙颖超,唐玲.双氢青蒿素抑制肝癌细胞侵袭和转移的初步研究[J].中国中药杂志,2020,45(3):683-688. 被引量:16
  • 2Kulpeng W,Sompitak S,Jootar S,et al.Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-Line treatment with imatimib in Tailand[J].Clin Ther,2014,36(4):534-543.
  • 3Elias MH,Bada AA,Azlan H,et al.BCR-ABL kinase domain mutations,including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia p atients-Frequency and clinical outcome[J].Leuk Res,2014,38(4):454-459.
  • 4Mathisen MS,Kantarjian HM,Cortes J,et al.Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia[J].Blood Rev,2014,28(5):179-187.
  • 5Guihot F,Roy L,Saulnier PJ,et al.Interferon in chronic Myeloid Leukenia:past and future[J].Best Pract Res Clin Haematol,2009,22(3):315-329.
  • 6Sacha T,Hochhaus A,Hanfstein B,et al.ABL-kinase domain point mutations as a cause of imatinib(STI571)resistance in CML patients who progress to myeloid blast crisis[J].Leuk Res,2003,27(12):1163-1166.
  • 7Quinta's-Cardama A,Jabbour EJ.Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib[J].Leuk Res,2013,37(5):487-495.
  • 8Kralj E,Zakelj S,Trontelj J,et al.Absorption and elimiation of imatinib through the rat intestine in vitro[J].Int J Pharm,2014,460(1/2):144-149.
  • 9Shah NP,Nicoll JM,Nagar B,et al.Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib(STI571)Chronic phase and blast crisis chronic myeloid leukemia[J].Cancer Cell,2002,2(2):117-125.
  • 10Kalle AM,Sachchidanand S,Pallu R.BCR-Abl-independent mechanism of resistance to imatinib in K562 cells:Induction of cyclooxygenase-2(COX-2)by histone deacetylases(HDACs)[J].Leuk Res,2010,34(9):1132-1138.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部